Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference

Rhea-AI Summary

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO, will participate in a fireside chat at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 p.m. EDT. The event will be accessible via a live and archived webcast on the company’s Investors section of its website. Protagonist is known for its proprietary technology platform aimed at developing novel peptide-based therapeutics, including three clinical-stage assets like PTG-300 and PTG-200.

NEWARK, Calif., June 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual BMO Prescriptions for Success Healthcare Conference.

Presentation details:
Event: BMO Prescriptions for Success Healthcare Conference
Date: Tuesday, June 23, 2020
Time: 1:00 p.m. EDT

A live and archived webcast of the fireside chat can be accessed by visiting the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-bmo-prescriptions-for-success-healthcare-conference-301078273.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

What will Protagonist Therapeutics present at the BMO Healthcare Conference?

Protagonist Therapeutics will have a fireside chat led by CEO Dinesh V. Patel at the BMO Prescriptions for Success Healthcare Conference.

When is the BMO Prescriptions for Success Healthcare Conference?

The conference is scheduled for June 23, 2020.

What time will the Protagonist Therapeutics presentation take place?

The presentation will take place at 1:00 p.m. EDT.

How can I access the news from Protagonist Therapeutics?

You can access the webcast of the presentation on the Investors section of the Protagonist Therapeutics website.

What is the focus of Protagonist Therapeutics' clinical assets?

Protagonist Therapeutics focuses on developing peptide-based therapeutics for unmet medical needs, including treatments for polycythemia vera and inflammatory bowel disease.